Abstract:
In neuropsychological terms, neuroplasticity is the brain's ability to modify its structure and functions
throughout life, following learning, new experiences and environmental stimuli. This process involves the
formation of new connections (synapses) between neurons, ensuring the consolidation and/or recovery of lost
functions or the improvement of cognitive, affective, adaptive abilities, etc. depending on the needs. Many
mental health disorders due to cerebral neurochemical changes, but also the long-term action of psychoactive
remedies can negatively influence neuroplasticity, and in these clinical situations resistance to therapy can
develop. The aim of the study was to search the specialized scientific literature for information regarding the
possibilities of stimulating cerebral neuroplasticity in patients with mental health disorders. Scientific sources
published in the last decade from Medscape, Google Scholar, PubMed, were analyzed. Meta-analyses, clinical
studies, and relevant review articles were included. There are several clinical studies that demonstrate that
augmenting liposomal phospholipids to basic treatment (antipsychotic, antidepressant, etc.) increases its
effectiveness. The main arguments in this regard would be - liposomal phospholipids due to the action of
specific nanoparticles (phosphatidylserine, phosphatidylcholine, phosphatidylethanolamine, sphingomyelin,
phosphatidylinositol) increase the synthesis of neurotransmitters (serotonin, acetylcholine), reduce cortisol
concentration, prevent the reduction of dendritic spine density, thus maintaining cerebral neuroplasticity.
Augmenting liposomal phospholipids to treatment with antidepressants, antipsychotics: a) potentiates their
effect, by stimulating cerebral neurotransmission; b) maintains neuroplasticity; c) increases the quality of life
of patients with mental health disorder.
